34 Results for "

occupancy

" in MedChemExpress (MCE) Product Catalog:
Products (34)

34 Results for "occupancy" in MCE Product Catalog:

Cat. No.: HY-116062A
CAS No.: 129540-12-1
Research Areas:  

Neurological Disease

JNJ-7925476 is a triple reuptake inhibitor that selectively and potently inhibits the activity of the serotonin transporter (SERT), norepinephrine transporter (NET), and dopamine transporter (DAT). JNJ-7925476 is rapidly absorbed into the blood and its concentration in the brain is 7-fold higher than that in plasma. The occupancy ED(50) values of JNJ-7925476 for SERT, NET, and DAT in the rat brain are 0.18, 0.09, and 2.4 mg/kg, respectively. JNJ-7925476 rapidly induces a significant increase in the levels of extracellular serotonin, dopamine, and norepinephrine in the rat cerebral cortex in a dose-dependent manner. JNJ-7925476 exhibits potent antidepressant-like activity in the mouse tail suspension test. These results suggest that JNJ-7925476 has in vivo efficacy in biochemical and behavioral models of depression .
loading...
    loading...
Cat. No.: HY-167284
CAS No.: 76298-89-0
Synonyms: BrAAM
Target:  

Adrenergic Receptor

Research Areas:  

Cardiovascular Disease

Bromoacetylalprenololmenthane (BrAAM) is a competitive, slowly reversible β1-adrenoceptor antagonist with membrane-stabilizing effects. Bromoacetylalprenololmenthane causes parallel or non-parallel rightward shifts of the isoproterenol response curve and reversibly inhibits cardiac stimulatory responses. Bromoacetylalprenololmenthane can be used in studies such as determining the affinity constant of isoproterenol, occupancy-response relationships, and receptor reserve .
loading...
    loading...
Cat. No.: HY-165093
CAS No.: 81655-42-7
Synonyms: 1-Arachidin-2-olein-3-palmitin; TG(20:0/18:1/16:0)
Target:  

Others

Research Areas:  

Others

1-Arachidoyl-2-oleoyl-3-palmitoyl-rac-glycerol (1-Arachidin-2-olein-3-palmitin) is a triglyceride characterized by regioisomerism by silver ion HPLC/MS. The method can be applied to the analysis of complex samples of vegetable oils and animal fats, and the results show that plant and animal fats have different preferences for fatty acid occupancy at the sn-2 position.
loading...
    loading...
Cat. No.: HY-183859
CAS No.: 88017-05-4
Target:  

Adrenergic Receptor

Research Areas:  

Cardiovascular Disease

H142/08 is a β1-adrenergic receptor-selective agonist. H142/08 induces concentration-dependent relaxation of isolated rat uterus and acts as a chronotropic stimulant to increase atrial rate, and its effects are effectively antagonized by Pafenolol (HY-165495). H142/08 also antagonizes the chronotropic effect of isoproterenol on isolated rat right atrium, but requires a higher proportion of receptor occupancy to produce sufficient stimulatory effects .
loading...
    loading...
Cat. No.: HY-W743023
CAS No.: 13389-16-7
8-Aminoinosine is a purine nucleoside phosphorylase (PNPase) inhibitor with a Ki value of 35 μM for the human target. 8-Aminoinosine exerts indirect competitive inhibition through two mechanisms: competitive substrate occupancy and metabolic conversion to the PNPase inhibitor (8-Aminohypoxanthine). 8-Aminoinosine induces increased urine output, sodium excretion, and glucose excretion, without altering potassium excretion. 8-Aminoinosine can be used in research related to hypertension, heart failure, and chronic kidney disease .
loading...
    loading...
Cat. No.: HY-W471288
CAS No.: 30479-81-3
Synonyms: JFD 00458
Target:  

AP-1

Research Areas:  

Neurological Disease

JPC0661 is a direct and allosteric ΔFOSB inhibitor. JPC0661 inhibits the binding of ΔFOSB/JUND and ΔFOsB to DNA with IC50 values in the micromolar range (9-52 uM), directly inhibits ΔFOSB-mediated transcription with IC50 of 0.82 μM in vitro. JPC0661 significantly reduces ΔFOSB occupancy at genomic AP1 sites in vivo. JPC0661 binds to a novel groove outside the DNA-binding cleft of ΔFOSB and disrupt the formation of the ΔFOSB/JUND-DNA complex. JPC0661 can be used for Alzheimer's disease research .
loading...
    loading...
Cat. No.: HY-B0368B
CAS No.: 119238-52-7
D-Captopril is a NDM-1 inhibitor and a competitive BlaB inhibitor, with an IC50 value of 21.8 µM against NDM-1 and a Ki of 70-100 µM against BlaB. D-Captopril synergistically reduces the minimum inhibitory concentration of Meropenem (HY-13678) against NDM-1-expressing bacteria. D-Captopril binds to BcII via its thiolate sulfur atom and carboxylate group, altering metal ion occupancy and modulating Cd 2+ binding affinity. D-Captopril can be used in the research of neonatal meningitis, sepsis and bacterial infections .
loading...
    loading...
Cat. No.: HY-P992448

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

RC98 is a monoclonal antibody targeting programmed cell death ligand 1 (PD-L1) and acts as a selective PD-L1 inhibitor. RC98 binds specifically to human and cynomolgus monkey PD-L1. RC98 blocks the interaction between PD-L1 and its receptor PD-1 to reverse T-cell inactivation mediated by PD-1/PD-L1 signaling. RC98 enhances the cytotoxic T-lymphocyte-mediated anti-tumor immune response against PD-L1-expressing tumor cells. RC98 can be used for the research of tumor immunity and solid tumors .
loading...
    loading...
Cat. No.: HY-181065
CAS No.: 3099617-79-2
Research Areas:  

Cancer

LS-170 is a YEATS2 YEATS domain inhibitor with an IC50 of 0.14 μM. LS-170 displays selectivity for the YEATS2 YEATS domain over other YEATS domain family members and other epigenetic 'reader' and 'eraser' proteins. LS-170 reduces chromatin occupancy of the Ada-two-A-containing (ATAC) complex, decreases ATAC-dependent histone acetylation levels, and downregulates expression of ATAC-governed genes. LS-170 suppresses tumor growth in a lung cancer mouse model. LS-170 can be used for the research of non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-165444
CAS No.: 329016-45-7
Synonyms: NGD-913
Target:  

GABA Receptor

Research Areas:  

Neurological Disease

CP-615003 is a potent and subtype-selective partial agonist of GABAA receptor (GABAA receptor) (Ki = 1.1 μM). CP-615003 is mainly converted into the active metabolite CP-900725 through oxidative deamination in monkeys and humans, and the latter also has GABAA receptor affinity. CP-615003 is a substrate of P-glycoprotein (P-gp/MDR1), resulting in severe limitation of its penetration into the central nervous system (CNS). CP-615003 can be used for the study of CNS-related indications .
loading...
    loading...
Cat. No.: HY-P1758A
Synonyms: IRRP1 acetate
Target:  

IFNAR STAT Influenza Virus

Research Areas:  

Infection

IFN-α Receptor Recognition Peptide 1 acetate (IRRP1 acetate) is an amino acid synthetic peptide and also a regulator of IFN-α Receptor. IFN-α Receptor Recognition Peptide 1 acetate binds to IFNAR2, enhances the binding capacity of IFN-α receptor, and slightly increases the IFN-α-induced growth inhibitory activity. IFN-α Receptor Recognition Peptide 1 acetate inhibits IFN-α-induced STAT1 phosphorylation and STAT-DNA binding by blocking the activation of IFNAR by IFN-α. IFN-α Receptor Recognition Peptide 1 acetate increases the occupancy of IFN-α on cell surface receptors, enhances the phosphorylation activation of ISGF3, and elevates IFN-α-induced antiviral activity. IFN-α Receptor Recognition Peptide 1 acetate can be used in studies related to encephalomyocarditis virus infection .
loading...
    loading...
Cat. No.: HY-L036
1,618 compounds

Small molecule covalent inhibitors, or irreversible inhibitors, are a type of inhibitors that exert their biological functions by irreversibly binding to target through covalent bonds. Compared with non-covalent inhibitors, covalent inhibitors have obvious advantages in bioactivity, such that covalent warheads can target rare residues of a particular target protein, thus leading to the development of highly selective inhibitors and achieving a more complete and continued target occupancy in living systems. In recent years, the distinct strengths of covalent inhibitors in overcoming drug resistance had been recognized. However, toxicity can be a real challenge related to this class of therapeutics due to their potential for off-target reactivity and has led to these drugs being disfavored as a drug class. The drug design and optimization of covalent inhibitors has become a hot spot in drug discovery.

MCE covalent inhibitor library contains 1,618 small molecules including identified covalent inhibitors and other bioactive molecules having common covalent reactive groups as warheads, such as acrylamides, activated terminal acetylenes, Sulfonyl fluorides/esters, cloracetamides, alkyl halides, epoxides, aziridines, disulfides, etc.

Cat. No.: HY-L908
1,244 compounds

Small molecule covalent inhibitors, or irreversible inhibitors, are a type of inhibitors that exert their biological functions by irreversibly binding to target through covalent bonds. Compared with non-covalent inhibitors, covalent inhibitors have obvious advantages in bioactivity, such that covalent warheads can target rare residues of a particular target protein, thus leading to the development of highly selective inhibitors and achieving a more complete and continued target occupancy in living systems. In recent years, the distinct strengths of covalent inhibitors in overcoming drug resistance had been recognized. However, toxicity can be a real challenge related to this class of therapeutics due to their potential for off-target reactivity and has led to these drugs being disfavored as a drug class. The drug design and optimization of covalent inhibitors has become a hot spot in drug discovery.

MCE Lead-like Covalent Screening Library offers a valuable resource of 1,049 lead-like compounds with commonly used covalent warheads. These warheads, such as acrylamide, activated terminal alkyne, acyloxymethyl ketone, and boronic acid, are capable of reacting with specific amino acid residues, including cysteine, lysine, serine, and histidine. The inclusion of these reactive warheads in the library allows researchers to explore the potential of covalent inhibition, a powerful approach in drug discovery.

Cat. No.: HY-L036P
6,121 compounds

Small molecule covalent inhibitors, or irreversible inhibitors, are a type of inhibitors that exert their biological functions by irreversibly binding to target through covalent bonds. Compared with non-covalent inhibitors, covalent inhibitors have obvious advantages in bioactivity, such that covalent warheads can target rare residues of a particular target protein, thus leading to the development of highly selective inhibitors and achieving a more complete and continued target occupancy in living systems. In recent years, the distinct strengths of covalent inhibitors in overcoming drug resistance had been recognized. However, toxicity can be a real challenge related to this class of therapeutics due to their potential for off-target reactivity and has led to these drugs being disfavored as a drug class. The drug design and optimization of covalent inhibitors has become a hot spot in drug discovery.

MCE covalent inhibitor library contains 6,121 small molecules including identified covalent inhibitors and other molecules having common covalent reactive groups as warheads, such as acrylamides, activated terminal acetylenes, sulfonyl fluorides/esters, cloracetamides, alkyl halides, epoxides, aziridines, disulfides, etc.

MCE Covalent inhibitor Library plus, with more powerful screening capability, further complement Covalent inhibitor Library (HY-L036) by adding some fragment compounds with covalent warheads.